CEPI to fund Phase 3 trial for Moderna’s mRNA-1018 vaccine candidate

The Coalition for Epidemic Preparedness Innovations will invest up to $54.3M to support a pivotal Phase 3 clinical trial that aims to help advance Moderna’s (MRNA) investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018, to licensure. The funding marks a significant step forward in global pandemic preparedness that could enable fast, equitable access to vaccines for one of the world’s most pressing health threats. This Phase 3 study would be the first mRNA-based vaccine targeting pandemic influenza to enter a pivotal trial. If the vaccine candidate is licensed, it would expand the current global portfolio of H5 vaccines with a rapid-response platform that could revolutionize future pandemic responses, making a significant contribution to CEPI’s 100 Days Mission, a global goal to develop safe and effective vaccines within 100 days of a new pandemic threat being identified.